A-ha frontman Morten Harket diagnosed with Parkinson's disease
The 65-year-old has been lead singer of the Norwegian band since it was founded in 1982 - and sung the track "Take On Me" which remains one of the most popular songs of the 1980s.
In a statement on the band's website, and confirmed by record label Sony Music, Harket said he had undergone
several rounds of brain surgery and that he was managing the symptoms of the disease.
Parkinson's causes deterioration in the brain's nervous system, leading to tremors and other symptoms that can become
progressively worse over time.
The disease can be treated with surgery and medication, but there is no cure.
Harket said he underwent neurological procedures to have electrodes implanted inside his brain last year and that this had reduced the symptoms.
Known for the wide range of his voice, Harket said he did not know if he would be able to perform again.
"I've got no problem accepting the diagnosis," he said, adding that it was difficult to balance medication and managing
side effects of the treatment.
"I'm trying the best I can to prevent my entire system from going into decline," Harket said.
Formed in 1982 by Harket and his friends Paul Waaktaar-Savoy and Magne Furuholmen, A-ha saw a global breakthrough in 1985 with their debut album "Hunting High and Low" featuring "Take On Me" and the hit "The Sun Always Shines on TV".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
4 hours ago
- The Guardian
ADHD medication linked to lower risk of suicidal behaviours, study suggests
Attention deficit hyperactivity disorder medication is linked to significantly lower risk of suicidal behaviours, substance misuse, transport accidents and criminality, according to a study of the wider outcomes of treatment. The research, based on the medical records of nearly 150,000 people in Sweden, suggested that the drugs could have meaningful benefits beyond helping with the core symptoms of ADHD. Although the study was not a randomised trial – and so cannot definitively prove that medication caused improved outcomes – it adds to evidence of the substantial value of treatment. 'We found that ADHD medication was associated with significantly reduced rates of first occurrences of suicidal behaviours, substance misuse, transport accidents and criminality,' said Prof Samuele Cortese, a child and adolescent psychiatrist and researcher at the University of Southampton. 'Our results should inform the debate on the effects and safety of ADHD medications.' After accounting for factors including age, sex, education level, psychiatric diagnoses and medical history, ADHD medication was associated with reduced rates of a first occurrence of four of the five outcomes investigated: a 17% reduction for suicidal behaviour, 15% for substance misuse, 12% for transport accidents and 13% for criminality. It is well established that ADHD, thought to affect about 5% of children and 2.5% of adults worldwide, is linked to higher rates of mental health problems including suicide, substance misuse and accidental injuries. People with ADHD are also disproportionately represented within the criminal justice system. Randomised clinical trials have demonstrated that for many patients, medication can help alleviate hyperactivity, impulsivity and the inattention. But there has been more limited evidence on whether these improvements translate into benefits in everyday life, at a time when the increasing number of people being diagnosed has fuelled a debate about the possibility of 'overdiagnosis'. The number of prescriptions being issued in England for attention deficit hyperactivity disorder (ADHD) medication has risen by 18% year on year since the pandemic. The latest study, which the researchers say is the largest and most rigorous of its kind, used Swedish national registers from 2007 to 2020 to examine the effects of ADHD drug treatment in 148,581 individuals aged six to 64 years with a new diagnosis of ADHD. The team used a technique called target trial emulation, which aims to apply the design principles of a clinical trial to existing medical records through the use of strict inclusion criteria, follow-up timeframes and the use of statistical techniques to compensate for the fact that people were not randomly assigned to 'treatment' or 'placebo' arms. Dr Zheng Chang, an epidemiologist at the Karolinska Institute in Stockholm and senior author of the research, said: 'It's now considered one of the most rigorous methods for analysing observational data. However, since we don't have the real randomisation data it is not bias-proof.' Sign up to First Edition Our morning email breaks down the key stories of the day, telling you what's happening and why it matters after newsletter promotion Of the 148,581 individuals with ADHD (average age 17 years, 41% female), 84,282 (57%) started drug treatment for ADHD, with methylphenidate being the most common. After adjusting for potential confounding factors, those who took medication had a reduced risk of first occurrence of suicidal behaviour, substance misuse, transport accidents and criminality, although there was no significant risk reduction for a first occurrence of accidental injury. Among people with recurrent events, there were statistically significant reductions linked to all five outcomes, the paper in the British Medical Journal reports. 'When clinicians discuss the possible use of medication with families, oftentimes there is not a focus on what are the risks if you don't treat,' said Cortese. 'If left untreated, there will be unfortunately some risk. Now we have evidence that medication can reduce this risk.' Prof Adam Guastella, of the Children's Hospital Westmead Clinical School at the University of Sydney, said: 'Such benefits have been shown repeatedly in previous studies, but the large sample size, use of a national registry, and more sophisticated analysis give greater confidence in these results that findings aren't explained by something else other than medication use. 'People should know that if ADHD medications work for them and their child, that there will likely be many other positive impacts on life from treatment. Such effects will not work for everyone and there is still a need to understand why many individuals benefit from ADHD medication and some do not.'
The Guardian
6 hours ago
- The Guardian
Next manuscript by Amitav Ghosh to be kept sealed for 89 years
The next manuscript by Indian writer Amitav Ghosh will not be read for 89 years, as he becomes the 12th author to contribute to the Future Library project. Ghosh joins Margaret Atwood, Han Kang, Ocean Vuong and other prominent authors who have written secret manuscripts, which are locked away until 2114. The texts are stored in a specifically designed silent room in the Deichman Bjørvika building at the public library in Oslo. At the end of the project, the full anthology of texts will be printed using paper made from trees from the Future Library forest in Nordmarka, in northern Oslo, where 1,000 spruce trees were planted by Katie Paterson, the artist behind the project, in 2014. Ghosh, whose novels include The Circle of Reason and Sea of Poppies, said being invited to participate in the Future Library project was a 'profound honour and a humbling act of trust'. The initiative 'compels us to think beyond our lifetimes, to imagine readers who have not yet been born'. 'It is particularly significant for me that the project has a forest at its core', he added, 'because for a long time now, I have been writing about a forest, albeit of an entirely different kind – the great mangrove forest known as the Sundarban'. Stretching across the Ganges delta, the Sundarbans are the backdrop to Ghosh's novels The Hungry Tide, Jungle Nama and Gun Island. 'It will be an exciting challenge to make a connection between the forests of the far north and those of the tropics, at this time of extreme planetary crisis,' added Ghosh, whose works often address climate disaster. 'I am moved to be part of a work that intertwines ecology, literature and patience on such a monumental scale.' Ghosh grew up in India, Bangladesh and Sri Lanka, and has a doctorate in social anthropology from the University of Oxford. He has written a number of novels, as well as works of nonfiction and essay collections. Ghosh's writing 'is expansive, urgent, and deeply attuned to the shifting ground of our world', said Paterson. 'His stories traverse oceans and centuries, revealing how the climate crisis is inseparable from histories of empire, migration and myth.' Sign up to Bookmarks Discover new books and learn more about your favourite authors with our expert reviews, interviews and news stories. Literary delights delivered direct to you after newsletter promotion 'With a rare ability to weave the intimate with the planetary, the visible with the invisible, Ghosh gives voice to the forces – human and more-than-human – that shape our shared future,' she added. Ghosh will submit his manuscript at a ceremony in the Future Library forest in May or June 2026, when the work's title will be revealed. Along with Atwood, Han and Vuong, other writers to have contributed to the project include David Mitchell, Sjón, Elif Shafak, Karl Ove Knausgård, Tsitsi Dangarembga, Judith Schalansky, Valeria Luiselli and, most recently, Tommy Orange. In June 2022, the City of Oslo signed an agreement which ensures the forest remains in the hands of the Future Library Trust for the duration of the project.
The Guardian
21 hours ago
- The Guardian
Oslo Stories Trilogy: Love review – gracefully grownup and breezy relationships drama
Here is the second of Norwegian film-maker and novelist Dag Johan Haugerud's seductive trilogy about affairs of the heart and mind, set in Oslo. (It comes between Sex and Dreams.) It is a thoroughly grownup and absorbing drama, acted with such sympathy and warmth, a ruminative and exploratory movie of ideas, and one that pays its audience the compliment of treating them as intelligent beings. Love is about a familiar question: can straight people learn from or even absorb the open and polygamous approach to sex that appears to come easier to gay people (and perhaps younger people of all sexualities), perhaps specifically gay men? Or is that idea stereotypical and naive? Andrea Braein Hovig plays Marianne, a urology consultant whose job it is to give bad news to a succession of men about their prostate cancer. She is single (though her past romantic life remains a mystery); her best friend, Heidi (Marte Engebrigtsen), tries to set her up with a divorced friend. But Marianne finds herself restive with the whole monolithic idea of dating and relationships and she is fascinated with what her nurse Tor (Tayo Cittadella Jacobsen) tells her about his own life. After work, she encounters him on their commuter ferry and he candidly tells her he uses Grindr to set up exciting, ephemeral encounters on this very craft. But it is Tor who is to develop serious feelings for one of his hook-ups – a urology patient at the hospital – and Marianne who experiments with openness, which is to upset others who feel obscurely threatened. Perhaps some of the characters are a bit too good to be true, and Marianne's shrewd warning to Tor about immediately developing a 'nurse' relationship to a partner is something whose implications are not heeded. Haugerud has something of Eric Rohmer, and perhaps a little more of Hong Sang-soo; a readiness to simply talk, and talk and talk some more. It's surprisingly cinematic. Oslo Stories Trilogy: Love is in UK and Irish cinemas from 15 August.
